文献速递肾移植

标准化诱导方案治疗的肾移植受者供者特异性抗HLA抗体特征与结局

Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

回顾性分析174例交叉配型阴性肾移植受者移植前血清DSA,采用Luminex技术检测,MFI>500为阳性,所有受者接受巴利昔单抗诱导和他克莫司维持免疫抑制。61/174例移植前存在DSA,I类和II类HLA-DSA同时存在且MFI>10000独立预测早期AMR风险增加(OR分别为4.24和4.75,P<0.05),此类患者5年移植物存活率最低(45%)。

要点

  • 移植前I类和II类HLA-DSA同时存在且MFI>10000独立预测早期AMR风险增加。
  • 仅I类或II类HLA-DSA或MFI<3000者AMR风险与未致敏患者相当。
  • 移植后14天DSA检测不到预测长期结局良好。

核心结论

  • 尽管采用非清除性抗体诱导,多数DSA阳性患者结局良好,而I类和II类HLA-DSA同时存在且DSA强度高者结局差,提示该人群需要差异化的治疗策略。

研究设计与样本

  • 回顾性分析174例接受交叉配型阴性肾移植患者的移植前血清,采用Luminex技术检测DSA。
  • DSA平均荧光强度(MFI)>500定义为阳性。
  • 所有受者接受巴利昔单抗诱导和他克莫司为基础的维持免疫抑制。
  • 对移植前存在DSA的患者进行移植后DSA监测。

主要发现

  • 61/174例患者移植前存在DSA。
  • I类和II类HLA-DSA同时存在与DSA MFI>10000强烈相关。
  • I类和II类HLA-DSA同时存在及MFI>10000均独立预测早期AMR风险增加(OR分别为4.24和4.75,P<0.05)。
  • 中间MFI(3000-10000)患者AMR风险随MFI升高逐渐增加,但组样本量太小无法得出最终结论。
  • 仅I类或II类HLA-DSA或MFI<3000的患者AMR风险与未致敏患者相当。

局限性

  • 中间MFI(3000-10000)组样本量太小,无法得出最终结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pre-transplant donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) have been associated with antibody-mediated rejection (AMR) and early kidney allograft loss. Uncertainties remain regarding the general applicability of these findings and the optimal induction therapy in DSA-positive patients. METHODS: Pre-transplant sera from 174 patients receiving a crossmatch-negative kidney transplant were retrospectively analysed for DSA using Luminex technology. DSA with mean-fluorescence intensity (MFI) values above 500 were considered positive. All recipients received basiliximab induction and tacrolimus-based maintenance immunosuppression. DSA were monitored post-transplantation in patients with pre-transplant DSA. Antibody results were correlated with the incidence of rejection and graft loss. RESULTS: In total, 61/174 patients had pre-transplant DSA. We found a strong correlation between the presence of DSA against class I and II HLA and DSA MFI greater than 10 000. Both DSA patterns independently predicted an increased risk of early AMR (odds ratio 4.24 and 4.75, respectively, P < 0.05). The risk for AMR in patients with intermediate MFI (3000-10 000) gradually increased with increasing MFI but group sizes were too small to allow for final conclusions. The risk for AMR was comparable to nonsensitized patients in patients with only class I or II HLA-DSA or MFI below 3000. 5-year allograft survival was lowest in patients with simultaneous presence of class I and II HLA-DSA and MFI above 10 000 (45%) but was comparable between patients with only HLA class I or II or no DSA (90.0, 90.0 and 88.1%, respectively). AMR was the only independent predictor of graft loss. Undetectable DSA 14 days post-transplant predicted excellent long-term outcome. CONCLUSION: . The favourable outcome in the majority of DSA-positive patients despite non-depleting antibody induction and the poor outcome in patients with class I and II HLA-DSA and high DSA strength call for a differentiated therapeutic approach in this patient population.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zecher D, Bach C, Staudner C, et al. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen. Nephrol Dial Transplant. 2017. PMID: 28339671. doi:10.1093/ndt/gfw445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。